Shikang Meng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shikang Meng has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ying Zheng
University of Macau
2 shared publications - Zibei Lin
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China
2 shared publications - Lin Sun
Zhuhai Campus of Zunyi Medical University, Department of Pharmaceutical Sciences, China
1 shared publication - Long Xi
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China
1 shared publication - Lun Wang
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China
1 shared publication - Ping Li
Beijing Hospital of Traditional Chinese Medicine, Affiliated with Capital Medical University, Beijing, China
1 shared publication
Latest Publications
- 1 October 2019
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 182, 110352
Loading of water-insoluble celastrol into niosome hydrogels for improved topical permeation and anti-psoriasis activity
- 1 October 2019
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 182, 110352
Loading of water-insoluble celastrol into niosome hydrogels for improved topical permeation and anti-psoriasis activity
- Open Access
- 23 March 2018
- Published by Springer Nature in Chinese Medicine
- Vol. 13 (1) , 16
Psoriasis therapy by Chinese medicine and modern agents
Psoriasis is a chronic, painful, disfiguring and non-contagious skin disease that has globally affected at least 200 million patients. In general, mild to moderate psoriasis patients will be treated by chemical drugs or Chinese medicine, while targeting systemic biological drugs have been successfully developed with good efficacy but high cost burden to patients with severe psoriasis. Since the underlying mechanisms of psoriasis are not well understood, in this review, psoriasis pathogenesis and clinical therapeutic principles by modern medicine and Chinese medicine are extensively described. Based on the data from the China Food and Drug Administration, the majority of chemical drugs are utilized as the topical formulations, while Chinese medicines are mainly delivered by an oral route, suggesting that the market for topical preparations of Chinese medicine to treat psoriasis is worth to exploration. Moreover, considering the unique clinical therapeutic theory and successful clinical application of Chinese medicine in the treatment of psoriasis, we believe that development of new small molecule drugs based on Chinese medicine will be a promising strategy to reduce therapeutic costs and improve safety for psoriatic patients.
- 23 March 2018
- Published by Springer Nature in Chinese Medicine
- Vol. 13 (1) , 16
Open AccessPsoriasis therapy by Chinese medicine and modern agents
Psoriasis is a chronic, painful, disfiguring and non-contagious skin disease that has globally affected at least 200 million patients. In general, mild to moderate psoriasis patients will be treated by chemical drugs or Chinese medicine, while targeting systemic biological drugs have been successfully developed with good efficacy but high cost burden to patients with severe psoriasis. Since the underlying mechanisms of psoriasis are not well understood, in this review, psoriasis pathogenesis and clinical therapeutic principles by modern medicine and Chinese medicine are extensively described. Based on the data from the China Food and Drug Administration, the majority of chemical drugs are utilized as the topical formulations, while Chinese medicines are mainly delivered by an oral route, suggesting that the market for topical preparations of Chinese medicine to treat psoriasis is worth to exploration. Moreover, considering the unique clinical therapeutic theory and successful clinical application of Chinese medicine in the treatment of psoriasis, we believe that development of new small molecule drugs based on Chinese medicine will be a promising strategy to reduce therapeutic costs and improve safety for psoriatic patients.